Resumo

MORA, Claudia; DIAZ, Jorge  e  QUINTANA, Gerardo. Financial cost of early rheumatoid arthritis in the first year medical attention: three clinical scenarios. Biomédica [online]. 2009, vol.29, n.1, pp.43-50. ISSN 0120-4157.

Introduction. In Colombia, the cost burden of chronic diseases is not well known, either globally or in localized areas of the health system. Rheumatoid arthritis is one of most common chronic diseases, and represents a high cost for the health system. Objective. The direct medical costs were estimated for rheumatoid arthritis patients in the in the first year of diagnosis at a level 3 university hospital in Colombia. Materials and methods. Three therapy settings for early rheumatoid arthritis patients were established in the first year of diagnosis according to national and international guidelines. Each setting included treatment with disease-modifying anti-rheumatic drugs or biologic therapy based on disease severity as measured by Disease Activity Score 28. All direct medical costs were included: specialized medical care, diagnostic tests and drugs. Cost information was obtained from the Central Military Hospital finance department in Bogotá and the national manual of drug prices based on the “Farmaprecios” 2007 guide, a reference in general use by health institutions. Results. The average of cost of medical care in patients with mild, moderate and severe disease was US$1,689, $1,805 and $23,441 respectively. The recommended retail prices of the medicines published in “Farmaprecios” was US$ 1,418, $1,821 and $31,931. When the charges levied by several major health institutions were compared, substantial increases were noted, US$ 4,936, $ 7,716 and $ 123,661, respectively. Drug costs represented 86% of total cost, laboratory costs were 10% and medical attention was only 4%. Conclusions. Drugs costs were the principal component of the total direct medical cost, and it increased 40 times when a biological therapy is used. Complete economic evaluation studies are necesary to estimate the viability and clinical relevance of biological therapy for early rheumatoid arthritis.

Palavras-chave : rheumatoid, arthritis; costs and cost analysis; cost of illness; Colombia.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )